Document is current
Any future updates will be listed below
-
Authors
Xie, Jingyi
Chen, Daniel G. https://orcid.org/0000-0001-6660-6257
Chour, William https://orcid.org/0000-0003-1817-0123
Ng, Rachel H. https://orcid.org/0000-0003-3692-8524
Zhang, Rongyu
Yuan, Dan
Choi, Jongchan https://orcid.org/0000-0003-0394-9978
McKasson, Michaela
Troisch, Pamela
Smith, Brett https://orcid.org/0000-0002-2586-5014
Jones, Lesley
Webster, Andrew
Rasheed, Yusuf
Li, Sarah
Edmark, Rick
Hong, Sunga https://orcid.org/0000-0003-4412-2811
Murray, Kim M.
Logue, Jennifer K. https://orcid.org/0000-0002-7889-8960
Franko, Nicholas M. https://orcid.org/0000-0001-8165-6332
Lausted, Christopher G. https://orcid.org/0000-0003-3073-9212
Piening, Brian https://orcid.org/0000-0002-2683-8157
Algren, Heather
Wallick, Julie
Magis, Andrew T.
Watanabe, Kino
Mease, Phil
Greenberg, Philip D. https://orcid.org/0000-0003-3812-647X
Chu, Helen https://orcid.org/0000-0001-8502-9600
Goldman, Jason D. https://orcid.org/0000-0002-3825-6832
Su, Yapeng
Heath, James R. https://orcid.org/0000-0001-5356-4385
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (HHSO10201600031C)
- License Information
-
More Information
Article History
Received: 9 September 2024
Accepted: 27 January 2025
First Online: 6 February 2025
Competing interests
: J.R.H. is a consultant to Regeneron, and has received research support from Gilead and Merck. J.D.G. declared contracted research with Gilead, Lilly, and Regeneron. P.D.G. is on the Scientific Advisory Board of Affini-T, Catalio, Earli, Elpiscience, Fibrogen, Immunoscape, Metagenomi, Nextech, and Rapt; was a scientific founder of Juno Therapeutics and Affini-T; and receives research support from Lonza and Affini-T Therapeutics. H.C. reported consulting with Ellume, Pfizer, and the Bill and Melinda Gates Foundation and has served on advisory boards for Vir, Merck and Abbvie. H.C. has conducted CME teaching with Medscape, Vindico, Cataylst CME, and Clinical Care Options. H.C. has received research funding from Gates Ventures, and support and reagents from Ellume and Cepheid outside of the submitted work. The remaining authors declare no competing interests.
